If you’ve noticed weight gain around perimenopause or menopause, you’re not alone. Many women experience a shift toward more abdominal fat and changes in body composition during the menopausal transition, even when their habits haven’t changed—or frustratingly, when they’re working even harder to lose weight than they ever have before. Research following women through the final menstrual period shows that body composition can change unfavorably around this time, with increased fat gain and loss of lean mass.
That’s where GLP-1 medications (often called “GLP-1 agonists”) have entered the conversation.
What GLP-1 medications are
GLP-1 receptor agonists are prescription medications that were originally developed for type 2 diabetes and are now also used for weight management in some people. They work through multiple pathways, including appetite regulation (feeling full sooner and longer), slowing stomach emptying, and improving blood-sugar control.
Why menopause-related weight gain can be so stubborn
A common frustration is: “If low estrogen contributes to weight gain, why doesn’t replacing estrogen automatically fix it?”
Estrogen can be helpful for symptoms (hot flashes, sleep, vaginal symptoms) and may support body composition for some people, but it doesn’t reliably “reset” metabolism or reverse weight changes on its own. Menopause-related weight changes are influenced by multiple factors: aging, muscle loss, sleep disruption, stress, changes in activity and how the body stores fat.
GLP-1 medications are sometimes considered when weight gain is affecting health (blood pressure, insulin resistance, fatty liver, sleep apnea, joint pain) or when lifestyle efforts aren’t enough.
Potential benefits (beyond the scale)
In addition to supporting blood sugar and weight management, newer research suggests GLP-1 medications may also help reduce inflammation in the body. Because inflammation plays a role in many chronic pain conditions, some patients report improvements in joint pain and overall discomfort. Research is ongoing, but scientists are increasingly exploring these broader effects.
Not everyone needs these medications, but it’s helpful to know they are not “vanity drugs” for many patients — they can be powerful cardiometabolic tools.
Risks, side effects, and what “microdosing” really means
Common side effects are gastrointestinal: nausea, constipation, diarrhea, reflux, and reduced appetite. These are often dose-related and can improve with slower titration, hydration, adequate protein, and constipation prevention.
About “microdosing”: some clinics use this term to mean starting very low and increasing very gradually to improve tolerability. That approach can be reasonable, but it’s important to know that long-term outcomes for non-standard dosing strategies are less well studied. If someone is using doses far below what was studied in clinical trials, we have less certainty about benefits and durability.
What we don’t have yet is decades of data for weight-loss use across all groups. That said, we do have extensive evidence about the long-term health risks of untreated overweight and obesity for many people (cardiometabolic disease, fatty liver, sleep apnea, osteoarthritis), so the decision is often about balancing known risks against potential benefits.
The thyroid cancer question: where it came from, and what it means
The FDA boxed warning for semaglutide products (for example Ozempic/Wegovy) exists because rodents given semaglutide developed thyroid C-cell tumors. The label is clear that it’s unknown whether this applies to humans, and the “human relevance” of the rodent findings has not been determined. (FDA Access Data)
Why rodents may not equal humans: rodent thyroid C-cells appear to have higher GLP-1 receptor expression than humans, which may partly explain why tumor findings occurred in that species. Reviews in toxicologic pathology discuss these species differences and note much lower GLP-1 receptor expression in primates/humans compared with rodents.
What this means practically:
• These medications are generally avoided in people with a personal or family history of medullary thyroid cancer or MEN2, consistent with the prescribing information.
• For everyone else, the warning is worth understanding, but it should be interpreted in context: it came from rodent data, and translation to humans is uncertain. (FDA Access Data)
A note on estrogen, menopause, and GLP-1s
Sometimes GLP-1s are framed as “the fix” for menopause weight gain. A more accurate way to think about them is: one possible medical tool for some people, alongside (not instead of) sleep, nutrition, strength training, and stress support.
Menopause is associated with increased abdominal/visceral adiposity, which can raise cardiometabolic risk. Lifestyle strategies help, but some bodies still resist change because biology is powerful.
How we think about it at Inner MD
If you’re curious about GLP-1 therapy, the best next step is a thoughtful, stigma-free conversation focused on:
• your symptoms and health goals
• your metabolic risk markers
• prior weight history and what’s already been tried
• medication options, side effects, and what monitoring looks like
• a plan for maintaining muscle (protein + resistance training) and protecting mental well-being during appetite/weight changes
If you’re considering it, it shouldn’t feel like a moral decision. It’s a medical one. And it’s okay to decide it’s not for you, too.
What this means practically:
- These medications are generally avoided in people with a personal or family history of medullary thyroid cancer or MEN2, consistent with the prescribing information.
- For everyone else, the warning is worth understanding, but it should be interpreted in context: it came from rodent data, and translation to humans is uncertain. (FDA Access Data)
A note on estrogen, menopause, and GLP-1s
Sometimes GLP-1s are framed as “the fix” for menopause weight gain. A more accurate way to think about them is: one possible medical tool for some people, alongside (not instead of) sleep, nutrition, strength training, and stress support.
Menopause is associated with increased abdominal/visceral adiposity, which can raise cardiometabolic risk. Lifestyle strategies help, but some bodies still resist change because biology is powerful.
How we think about it at Inner MD
If you’re curious about GLP-1 therapy, the best next step is a thoughtful, stigma-free conversation focused on:
- your symptoms and health goals
- your metabolic risk markers
- prior weight history and what’s already been tried
- medication options, side effects, and what monitoring looks like
- a plan for maintaining muscle (protein + resistance training) and protecting mental well-being during appetite/weight changes
If you’re considering it, it shouldn’t feel like a moral decision. It’s a medical one. And it’s okay to decide it’s not for you, too.